Study of the pharmacokinetics and intragastric pH of rabeprazole given as successive intravenous infusion to healthy Chinese volunteers
- PMID: 21110014
- DOI: 10.1007/s00228-010-0949-4
Study of the pharmacokinetics and intragastric pH of rabeprazole given as successive intravenous infusion to healthy Chinese volunteers
Abstract
Objectives: To investigate the pharmacokinetics and pharmacodynamics of rabeprazole (RPZ) given as successive intravenous infusion to healthy Chinese volunteers.
Methods: A total of 63 subjects (33 males and 30 females) were recruited at four research centers and given a 5-day therapeutic course of RPZ (10, 20, or 40 mg) administered as single daily doses during a 30-min period. Plasma concentrations were monitored by sampling at very short intervals for the first 330, 360, or 420 min post-RPZ administration. Intragastric pH was recorded 24 h post-RPZ administration on day 1 and day 5.
Results: After receiving a single and repeated doses of RPZ, the area under the plasma concentration-time curve (AUC(0-τ)) was 51.9 ± 22.1, 96.7 ± 27.6, and 188.4 ± 65.8 mg·min/L on day 1 and 59.3 ± 23.9, 106.7 ± 27.8, and 200.3 ± 79.0 mg·min/L on day 5 for the low-, middle-, and high-dose groups, respectively. The corresponding peak concentrations (C(max)) were 0.64 ± 0.11, 1.30 ± 0.26, and 2.6 ± 0.54 μg/mL on day 1 and 0.76 ± 0.15, 1.39 ± 0.25, and 2.91 ± 0.53 μg/mL on day 5, respectively. Although the mean AUC and C(max) values increased from a single dose to repeated doses in the three groups, the difference was not significant. The mean AUC((0, τ)) and C(max) ratios of repeated dose to single dose were 1.14, 1.10, and 1.06 on day 1 and 1.19, 1.07, and 1.12 on day 5 for the low-, middle-, and high-dose groups, respectively. After administration of a single dose, the 24-h pH value was significantly higher in the high-dose group than in the low-dose group. After repeated doses, significant increases in pH were observed in the low-, middle-, and high-dose groups; however, the between-group differences were not statistically significant.
Conclusions: There is a relationship between the pharmacokinetics and pharmacodynamics of RPZ, with the latter depending in part on the duration of administration, as evidenced by a higher AUC or C(max) and intragastric pH from repeated dosing.
Similar articles
-
Influence of CYP2C19 on the relationship between pharmacokinetics and intragastric pH of omeprazole administered by successive intravenous infusions in Chinese healthy volunteers.Eur J Clin Pharmacol. 2010 Jun;66(6):563-9. doi: 10.1007/s00228-010-0821-6. Epub 2010 Apr 23. Eur J Clin Pharmacol. 2010. PMID: 20414645
-
Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotype in healthy Chinese subjects.Acta Pharmacol Sin. 2005 Mar;26(3):384-8. doi: 10.1111/j.1745-7254.2005.00047.x. Acta Pharmacol Sin. 2005. PMID: 15715938
-
Pharmacodynamic and kinetic effect of rabeprazole on serum gastrin level in relation to CYP2C19 polymorphism in Chinese Hans.World J Gastroenterol. 2006 Aug 7;12(29):4750-3. doi: 10.3748/wjg.v12.i29.4750. World J Gastroenterol. 2006. PMID: 16937451 Free PMC article. Clinical Trial.
-
Dose-response relationships of rabeprazole 5, 10, 20, and 40 mg once daily on suppression of gastric acid secretion through the night in healthy Japanese individuals with different CYP2C19 genotypes.Eur J Clin Pharmacol. 2012 May;68(5):579-88. doi: 10.1007/s00228-011-1164-7. Epub 2011 Nov 23. Eur J Clin Pharmacol. 2012. PMID: 22108775 Clinical Trial.
-
Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.Int J Clin Pharmacol Ther. 2006 Jul;44(7):297-302. doi: 10.5414/cpp44297. Int J Clin Pharmacol Ther. 2006. PMID: 16961157 Review.
Cited by
-
Effects of CYP2C19 genetic polymorphisms on the cure rates of H. pylori in patients treated with the proton pump inhibitors: An updated meta-analysis.Front Pharmacol. 2022 Oct 6;13:938419. doi: 10.3389/fphar.2022.938419. eCollection 2022. Front Pharmacol. 2022. PMID: 36278195 Free PMC article.
-
Safety, tolerability, pharmacokinetics and pharmacodynamics of dexlansoprazole injection in healthy Chinese subjects.Eur J Clin Pharmacol. 2017 May;73(5):547-554. doi: 10.1007/s00228-017-2206-6. Epub 2017 Jan 31. Eur J Clin Pharmacol. 2017. PMID: 28138748
-
A Whole-Body Physiologically Based Pharmacokinetic Model Characterizing Interplay of OCTs and MATEs in Intestine, Liver and Kidney to Predict Drug-Drug Interactions of Metformin with Perpetrators.Pharmaceutics. 2021 May 11;13(5):698. doi: 10.3390/pharmaceutics13050698. Pharmaceutics. 2021. PMID: 34064886 Free PMC article.
-
Impact of Gastric H+/K+-ATPase rs2733743 on the Intragastric pH-Values of Dexlansoprazole Injection in Chinese Subjects.Front Pharmacol. 2017 Sep 22;8:670. doi: 10.3389/fphar.2017.00670. eCollection 2017. Front Pharmacol. 2017. PMID: 29018343 Free PMC article.
-
Safety and tolerability of bismuthyl ecabet suspension, a novel anti-ulcer agent, following single and multiple oral dose administration in healthy Chinese subjects.Clin Drug Investig. 2012 Apr 1;32(4):247-52. doi: 10.2165/11599110-000000000-00000. Clin Drug Investig. 2012. PMID: 22299715 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources